Genetic technology applied to medicine

Recombinant human insulin was the first medicine produced by recombinant DNA technology (approved 1982). Today essentially all insulin used worldwide is recombinant. The complete production pathway has eight stages.

Step 1 — Obtain the insulin gene. Two approaches:

• (a) From mRNA. Pancreatic β-cells express insulin at high levels. Total mRNA is extracted (often using oligo-dT magnetic beads that bind the poly-A tail). Reverse transcriptase synthesises a cDNA copy of the insulin mRNA. The mRNA is degraded with RNase H, and DNA polymerase makes the second strand → double-stranded cDNA.
• (b) Chemical synthesis. Today, the known insulin nucleotide sequence is simply ordered from a DNA synthesis company.

Step 2 — Use cDNA, not genomic DNA. Eukaryotic genes contain introns — non-coding sequences spliced out of pre-mRNA before translation. Bacteria lack the spliceosome and cannot remove introns from a transcribed eukaryotic gene. cDNA is made from mature mRNA in which introns have already been removed, so bacteria can transcribe and translate it directly into functional insulin.

Step 3 — Cut the insulin gene and the vector. A restriction endonuclease (e.g. EcoRI) is chosen that cuts at sites flanking the insulin gene. EcoRI recognises the palindromic sequence GAATTC and cuts between G and A, leaving single-stranded sticky-end overhangs (5'-AATT-3').

The plasmid vector is cut with the same restriction enzyme, generating identical sticky ends on the linearised plasmid. Because both fragments now have complementary overhangs, they will base-pair specifically.

Step 4 — Ligate insulin gene into plasmid. The cut insulin gene + cut plasmid + DNA ligase are mixed. Complementary sticky ends base-pair by hydrogen bonding. DNA ligase catalyses the formation of phosphodiester bonds between the 3'-OH and 5'-phosphate of adjacent nucleotides, sealing the nicks on both strands. The product is a recombinant plasmid containing the insulin gene and a marker gene (typically antibiotic resistance, e.g. ampR).

Step 5 — Transform bacteria. The recombinant plasmid is introduced into E. coli by either:

• Electroporation — high-voltage electric pulse makes membrane briefly permeable, OR
• Heat-shock of CaCl₂-treated chemically competent cells (held on ice, briefly heated to 42 °C, then back on ice).

Only a small fraction of cells (typically 0.0001-0.1%) take up the plasmid — transformation must be followed by selection.

Step 6 — Select transformed bacteria. Bacteria are spread on agar plates containing ampicillin (or another antibiotic). Only cells carrying the plasmid + ampR gene survive and grow into colonies — they produce β-lactamase, which inactivates the antibiotic. Untransformed cells are killed. Blue-white screening (X-gal + disrupted lacZ) can be used additionally to confirm that the insulin gene insert is present (white colonies) rather than an empty self-ligated plasmid (blue colonies).

Step 7 — Industrial fermentation. Selected transformed E. coli are grown in large-scale bioreactors (fermenters of 10,000+ litres) under tightly controlled conditions:

• Nutrient broth supplying glucose, amino acids, salts.
• Temperature ~37 °C.
• Aeration (oxygen sparging) and stirring.
• pH controlled (typically ~7).
• IPTG or another inducer added to switch on insulin gene expression.

The bacteria multiply rapidly, doubling every 20-30 minutes, and each cell produces large amounts of human insulin protein.

Step 8 — Harvesting and purification. When the culture reaches high density, bacteria are harvested by centrifugation, lysed (cells broken open by sonication or chemical lysis) to release the insulin. The protein is purified by a series of chromatography steps (ion-exchange, gel filtration, affinity chromatography). Insulin is then correctly folded (forming the two disulphide bridges between the A and B chains), formulated into the final pharmaceutical product, sterilised and packaged for distribution.

The product is chemically identical to insulin produced naturally in the human pancreas — same amino acid sequence, same three-dimensional structure, same biological activity. It is used by an estimated 425 million diabetics worldwide.

For more than 50 years before recombinant DNA technology, diabetics relied on insulin extracted from the pancreases of slaughtered pigs and cattle. Pig insulin differs from human insulin by one amino acid; cow insulin by three. Recombinant human insulin (approved 1982) offers four significant advantages.

(1) Identical to human insulin — no immune response.

Recombinant insulin has exactly the same amino acid sequence as natural human insulin (because it is produced from the same gene). The one to three amino acid differences in pig/cow insulin make them mildly foreign to the human immune system. Some patients developed antibodies against animal insulin over years of treatment, causing:

• Reduced effectiveness (antibodies neutralise the insulin).
• Allergic reactions at injection sites.
• Rare cases of insulin allergy requiring desensitisation.

Recombinant human insulin eliminates these immune complications, giving smoother, more predictable blood glucose control over a lifetime of treatment.

(2) Unlimited and scalable supply.

Bacteria multiply in fermenters every 20-30 minutes, so production scales rapidly to meet demand. A single 10,000-litre fermenter can produce kilograms of insulin in a single batch.

Animal-derived insulin was severely supply-limited:

• Required pancreas glands from slaughterhouse animals.
• Roughly 8,000 pounds of pancreas glands to produce 1 pound of insulin.
• Could not keep pace with the rising global diabetes epidemic (now ~425 million people worldwide).
• Supply fluctuated with the meat industry.

Recombinant insulin removed this constraint and made supply effectively unlimited at affordable cost (in wealthy countries — affordability remains a global health concern).

(3) Ethical and religious acceptability.

Many patients object to using pork or beef for personal medical care:

• Muslims and Jews avoid pork; some object to beef-derived products from non-kosher / non-halal sources.
• Hindus revere cattle and avoid beef.
• Vegetarians and vegans object to animal-derived medicines on ethical grounds.

Recombinant insulin produced in bacteria involves no animal slaughter and is acceptable across all these groups.

(4) Lower contamination risk and consistent quality.

Animal pancreases can carry animal pathogens: porcine retroviruses, prions (BSE concerns in cattle), bacterial contamination. While purification removes most contaminants, residual risk remained. Recombinant production in well-characterised bacterial strains under controlled conditions:

• Avoids all animal pathogens by definition.
• Produces consistent quality between batches.
• Allows easy quality control through standard biotechnology methods.

Production can also be modified to make fast-acting or slow-acting insulin analogues (e.g. insulin lispro, insulin glargine) — variants with altered amino acid sequences that change absorption kinetics. These are impossible with animal extraction.

For all these reasons, recombinant insulin completely replaced animal insulin in wealthy countries within ~20 years of its 1982 introduction. Animal insulin is now used only in rare cases of patient preference or product shortage.

Gene therapy aims to correct a faulty gene by introducing a working copy (or, with CRISPR, by editing the faulty copy directly). Two fundamentally different approaches are distinguished by which cells are modified.

Somatic gene therapy.

Targets somatic (body) cells of an individual patient. Examples:

• SCID-X1 (severe combined immunodeficiency, X-linked) — bone marrow stem cells are removed, the corrective IL2RG gene is delivered using a retroviral or lentiviral vector, modified cells are returned to the patient. Has produced complete cures for many SCID-X1 patients.
• Beta-thalassaemia and sickle-cell anaemia — recently approved Casgevy treatment edits patients' own haematopoietic stem cells using CRISPR.
• Inherited retinal dystrophies — Luxturna (FDA approved 2017) injects a corrective RPE65 gene into retinal cells.
• Cystic fibrosis — inhaled liposomes or viral vectors deliver CFTR gene to lung cells (limited success so far).

Characteristics of somatic gene therapy:

• Only the patient is affected.
• Not inherited — gametes are not modified, so the genetic change is not passed to offspring.
• Often not permanent: cells targeted (especially short-lived ones like lung epithelium) die and are replaced by untreated cells from stem cells. Repeated treatment may be needed.
• Currently legal worldwide; many approved therapies in clinical use.

Germline gene therapy.

Modifies the gametes (sperm or egg) or the early embryo, so that every cell of the resulting organism — including its own gametes — carries the corrected gene.

Characteristics:

• Genetic change is heritable — passed to all offspring of the treated individual.
• Permanent: a single treatment fixes the condition for that individual and all descendants.
• Currently illegal in humans in most countries (including UK, USA, Germany, France and over 40 others).

Why germline gene therapy is illegal in humans.

(1) Lack of consent from those affected. A modified embryo cannot consent to its own genetic modification, nor can its future descendants — yet they all inherit the change. This violates a fundamental principle of medical ethics (informed consent).

(2) Irreversible and propagating. Any error or unintended effect (off-target editing, mosaicism, unexpected developmental consequences) is inherited indefinitely. Conventional medicine errors can be corrected; germline edits cannot.

(3) 'Designer babies' concern. Germline editing technology could in principle be used not just to fix disease alleles but to introduce 'enhancements' — height, intelligence, eye colour, athletic ability. This raises concerns about:

• Eugenics — historical horrors of forced sterilisation programmes.
• Social inequality — only the wealthy could afford enhancements.
• Loss of human genetic diversity.

(4) The Jiankui He case (2018). Chinese scientist He Jiankui announced he had used CRISPR to edit the genomes of two human embryos to confer HIV resistance. The work was universally condemned as scientifically unjustified, ethically reckless and inadequately reviewed; he was jailed for three years in China. The case galvanised international consensus against germline editing of humans.

(5) Sufficient alternatives. Pre-implantation genetic diagnosis (PGD) combined with IVF allows screening of embryos for serious disease alleles — achieving the goal of disease-free offspring without permanent germline modification. This makes germline editing less necessary even for serious genetic diseases.

Despite the prohibition, germline editing is routinely used in agricultural animals and plants for crop improvement — a different ethical context.

CRISPR-Cas9 is a revolutionary gene-editing technology developed in the early 2010s. Its inventors Jennifer Doudna and Emmanuelle Charpentier were awarded the 2020 Nobel Prize in Chemistry.

Natural origin. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) evolved in bacteria as an adaptive immune system against bacteriophage viruses. When a phage infects a bacterium that survives, fragments of the viral DNA are inserted into the bacterium's CRISPR locus between repeated sequences. On future infections, these fragments are transcribed into short guide RNAs that direct the Cas9 nuclease to find and cut matching viral DNA — destroying it.

In 2012, Doudna and Charpentier showed that this bacterial system could be repurposed as a programmable gene-editing tool by designing custom guide RNAs.

The two components.

(1) Cas9 — a protein nuclease that can cut both strands of double-stranded DNA at a specific site.

(2) Guide RNA (gRNA) — a short single-stranded RNA, approximately 20 nucleotides long, designed by the researcher to be complementary to the target DNA sequence to be edited.

The editing mechanism.

Step 1 — Assembly. The gRNA loads into Cas9, forming a Cas9-gRNA complex.

Step 2 — Target recognition. The complex scans the genome until the gRNA finds and base-pairs with its matching DNA target sequence by complementary base pairing. (A short sequence next to the target, the PAM site, also needs to be present.)

Step 3 — Cutting. Cas9 cuts both strands of the target DNA at a specific point — a double-strand break.

Step 4 — Repair = editing. The cell repairs the break using one of two pathways:

• Non-homologous end joining (NHEJ): error-prone direct rejoining of the broken ends, often introducing small insertions or deletions that disrupt the reading frame — effectively knocking out the target gene. Useful for studying what a gene does.

• Homology-directed repair (HDR): if a donor DNA template with the desired new sequence is provided, the cell can use it to repair the break, copying the new sequence into the genome. This allows precise edits — single base substitutions, insertions of new genes, deletions of specific sequences.

Why CRISPR transformed biology.

Compared with earlier gene-editing tools (zinc-finger nucleases, TALENs), CRISPR-Cas9 is:

• Vastly easier to design — just synthesise a 20-nt guide RNA.
• Cheap — a CRISPR experiment costs ~$50 in materials.
• Highly specific with appropriate gRNA design.
• Works in essentially any organism — from bacteria to plants to mammals.

Applications.

Application chosen: treatment of sickle-cell anaemia and β-thalassaemia (Casgevy, FDA-approved 2023).

Sickle-cell anaemia is caused by a single point mutation in the β-globin gene that distorts red blood cell shape. Casgevy treatment:

1. Patient's haematopoietic stem cells are harvested from bone marrow.
2. CRISPR-Cas9 is used to edit the BCL11A gene in those cells, reactivating fetal haemoglobin (HbF) expression. Fetal haemoglobin doesn't sickle.
3. The patient's bone marrow is destroyed by chemotherapy.
4. The edited cells are returned to the patient.
5. The edited stem cells produce blood cells with high fetal haemoglobin — symptoms largely resolved.

Casgevy is the first FDA-approved CRISPR therapy (December 2023) and a landmark in medicine. Other CRISPR clinical trials are underway for blindness (Leber congenital amaurosis), HIV, certain cancers and more.

Other applications include:

• Agriculture — disease-resistant rice, drought-tolerant wheat, larger livestock muscle mass.
• Research — making knockout mice and other model organisms.
• Drug screening — finding genes essential for disease processes.

Concerns include off-target editing (unintended cuts elsewhere in the genome), use in human embryos (Jiankui He case 2018), patent disputes over CRISPR-related inventions, and the question of equitable access to expensive CRISPR therapies.

Genetic screening tests an individual or embryo for specific disease alleles or chromosomal abnormalities. Modern screening covers a wide range — from newborn heel-prick tests for PKU and sickle-cell, to predictive testing for adult-onset diseases, to prenatal screening and pre-implantation genetic diagnosis. Each application raises ethical questions that must be weighed against medical benefit.

Benefits — the case for screening.

(1) Early diagnosis and treatment. Newborn screening for phenylketonuria (PKU) allows treatment with a low-phenylalanine diet to prevent severe brain damage. Without screening, many children would develop intellectual disability before diagnosis. Screening for sickle-cell disease similarly allows prophylactic penicillin to prevent fatal pneumococcal infection.

(2) Reproductive choices. Carrier screening — for example, in Ashkenazi Jewish populations for Tay-Sachs disease, or in populations at risk of thalassaemia — allows couples to know carrier status before deciding to have children. Some couples seek pre-implantation genetic diagnosis (PGD); others may decide not to conceive.

(3) Prophylactic intervention. Women testing positive for BRCA1 or BRCA2 mutations face very high lifetime breast and ovarian cancer risks (45-85% for BRCA1). Prophylactic mastectomy and/or oophorectomy can dramatically reduce risk. Angelina Jolie's 2013 announcement of prophylactic mastectomy following a BRCA1-positive test raised public awareness.

Concerns — the case against indiscriminate screening.

(1) Insurance and employment discrimination. A positive genetic test could lead to denial or higher premiums for life, health or disability insurance, or discrimination by employers. The US GINA Act (2008) prohibits this for health insurance and employment but not for life or disability insurance. The UK has a moratorium agreement between government and insurers. Many countries have weaker or no protection. Even where laws exist, fear of discrimination deters people from testing.

(2) Psychological impact of incurable late-onset disease. Testing for Huntington's disease — an autosomal dominant disorder with onset typically age 30-50, no cure, leading to dementia, movement disorder and death — presents a stark dilemma. A positive test gives decades of certainty that the person will develop a fatal disease. Many people from Huntington's families choose not to test, despite the availability. The psychological burden can include depression, anxiety, even suicide.

Family-wide implications: if one sibling tests positive, untested siblings learn their own risk is high. This can fracture family relationships and cause "genetic survivor's guilt".

(3) Prenatal screening and selective abortion. Modern non-invasive prenatal testing (NIPT) screens fetal DNA in maternal blood for Down syndrome (trisomy 21) and other conditions. In some countries, Down syndrome screening leads to high termination rates (>90% in Iceland and Denmark; ~70% in the UK).

This raises difficult questions:

• Which conditions justify termination? Lethal conditions vs disability?
• Are we drifting toward eugenics — the practice of trying to "improve" the human gene pool that produced 20th-century atrocities?
• Disability-rights advocates argue prenatal screening sends a message that disabled lives are less valuable.
• Others see this as a legitimate parental choice protected by reproductive autonomy.

(4) Disclosure to relatives. Genetic information has implications for biological relatives who share alleles. If a patient tests positive for a BRCA1 mutation, her siblings and children have a 50% chance of carrying the same allele. Should the patient be required to disclose to relatives? Should doctors warn relatives if the patient refuses (some jurisdictions allow this in exceptional circumstances)? The patient's right to privacy can conflict with relatives' right to information that affects their own health decisions.

(5) Equity and access. Genetic screening is expensive and unequally distributed globally. In wealthy countries, screening is increasingly part of routine care; in low- and middle-income countries it remains rare. Genetic databases also disproportionately represent European-descent populations, biasing risk calculations and missing variants common in other ethnicities — a problem known as genomic inequity.

Balanced conclusion.

Genetic screening offers profound medical benefits but also profound risks. The ethical balance differs by context:

• Newborn screening for treatable conditions (PKU, sickle-cell): clearly justified — benefit hugely outweighs concerns.
• Predictive testing for incurable late-onset disease (Huntington's): justified only with thorough counselling and the individual's clear choice.
• Prenatal screening: most controversial; raises eugenics concerns; requires careful societal debate about which conditions to test for.
• Carrier screening: helpful for informed reproductive choice; demands robust counselling.

Strong anti-discrimination laws (like the US GINA Act), genetic counselling to help patients understand results, and public engagement on policy decisions are essential to capture the benefits while limiting the harms.